Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05052970
Collaborator
(none)
60
Enrollment
1
Location
3
Arms
32
Anticipated Duration (Months)
1.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Condition or DiseaseIntervention/TreatmentPhase
  • Drug: Mitoxantrone Hydrochloride Liposome injection
  • Drug: Bortezomib for Injection
  • Drug: Dexamethasone Acetate Tablets
Phase 1

Detailed Description

This is a multicenter, open-label, phase I study aimed to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome injection in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. In the study, 60 patients will be recruited into three dose groups. All patients will receive the treatment for the planned 8 cycles(28 days per cycle)until disease progression or unacceptable drug-related adverse events

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Actual Study Start Date :
Oct 20, 2021
Anticipated Primary Completion Date :
Apr 20, 2023
Anticipated Study Completion Date :
Jun 20, 2024

Arms and Interventions

ArmIntervention/Treatment
Experimental: 12 mg/m ^ 2 dose group (ArmA)

Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 12 mg/m^2

Drug: Mitoxantrone Hydrochloride Liposome injection
Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
Other Names:
  • Mitoxantrone Hydrochloride Liposome
  • Drug: Bortezomib for Injection
    Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
    Other Names:
  • Bortezomib
  • Drug: Dexamethasone Acetate Tablets
    Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
    Other Names:
  • Dexamethasone
  • Experimental: 16 mg/m ^ 2 dose group (ArmB)

    Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 16 mg/m^2

    Drug: Mitoxantrone Hydrochloride Liposome injection
    Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
    Other Names:
  • Mitoxantrone Hydrochloride Liposome
  • Drug: Bortezomib for Injection
    Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
    Other Names:
  • Bortezomib
  • Drug: Dexamethasone Acetate Tablets
    Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
    Other Names:
  • Dexamethasone
  • Experimental: 20 mg/m ^ 2 dose group (ArmC)

    Patients with relapsed or refractory multiple myeloma will receive mitoxantrone hydrochloride liposome in combination with bortezomib and dexamethasone for 8 cycles (planned) (28 days per cycle). The dose of mitoxantrone hydrochloride liposome is 20 mg/m^2

    Drug: Mitoxantrone Hydrochloride Liposome injection
    Mitoxantrone Hydrochloride Liposome injection will be administered by an intravenous infusion on day 1 of each 28-day cycle
    Other Names:
  • Mitoxantrone Hydrochloride Liposome
  • Drug: Bortezomib for Injection
    Bortezomib (1.3 mg/m^2) will be administered by an intravenous injection or subcutaneously on day 1,4,8,11of each 28-day cycle
    Other Names:
  • Bortezomib
  • Drug: Dexamethasone Acetate Tablets
    Dexamethasone (20 mg/d) will be taken orally on day 1,2,4,5,8,9,11,12 of each 28-day cycle
    Other Names:
  • Dexamethasone
  • Outcome Measures

    Primary Outcome Measures

    1. Treatment-emergent adverse events (TEAEs) [From the initiation of the first dose to 28 days after the last dose]

      To indentify the incidence of TEAEs

    Secondary Outcome Measures

    1. Objective response rate (ORR) [Throughout the study treatment(Up to 32 weeks)]

      ORR is defined as the proportion of patients who have a best overall response of partial response (PR),very good partial response(VGPR), complete response (CR) or stringent complete response (sCR) as per International Myeloma Working Group (IMWG)

    2. Clinical Benefit Rate(CBR) [Throughout the study treatment(Up to 32 weeks)]

      CBR is defined as the proportion of patients who have a best overall response of minimal response(MR),PR,VGPR,CR or sCR as per IMWG

    3. Disease control rate(DCR) [Throughout the study treatment(Up to 32 weeks)]

      DCR is defined as the proportion of patients who have a best overall response of stable disease (SD),MR,PR,VGPR,CR or sCR as per IMWG

    4. Duration of response (DoR) [Throughout the study completion.(An average of 12 months)]

      DoR is defined as the time from the first assessment of PR,VGPR,CR orsCR until the date of first occurrence of progressive disease (PD) as per IMWG

    5. Progression-free survival (PFS) [Throughout the study completion.(An average of 12 months)]

      PFS is defined as the time from the date of first dose until the date of first documented PD as per IMWG or death from any cause, whichever occurs first

    6. Overall survival (OS) [Throughout the study completion.(An average of 36 months)]

      OS is defined as the time from the date of first dose until the date of death from any cause

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Patients fully understand and voluntarily participate in this study and sign informed consent;

    2. Aged 18-75 years, without gender limitation;

    3. Patients with relapsed or refractory multiple myeloma(confirmed by histologically or cytologically) who had received at least one prior line regular treatment;

    4. Patients have at least one of the following conditions:(1)Serum M protein≥10g/L;(2)Urine M protein≥200 mg/24h; (3)Serum free light chain(sFLC): κ/λ FLC ratio is abnormal and affected FLC ≥100mg /L

    5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

    6. Laboratory tests meet the following conditions:

    • Absolute neutrophil count (ANC) ≥1.5x10^9/L (No G-CSF treatment within 1 week prior to the laboratory test);

    • Platelet count ≥ 75x10^9/L (No platelet transfusion within 1 week prior to the laboratory test);

    • Total bilirubin ≤1.5upper limit of normal (ULN);

    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN;

    • Creatinine clearance(Ccr) ≥30mL/min.

    1. Females of childbearing potential must have a negative serum beta human chorionic gonadotrophin (β-hCG) pregnancy test result prior to enrollment and must agree to use an effective contraception method for the duration of the study treatment and 7 months after the last dose of study therapy.

    2. Males patients and their partners must agree to use an effective contraceptive method for the duration of the study treatment and 4 months after the last dose of study therapy.

    Exclusion Criteria:
    1. Patients with amyloidosis or central nervous system invasion or on dialysis treatment.

    2. Life expectancy < 3 months.

    3. History of allergy to mitoxantrone hydrochloride or liposomes;or previous treatment with adriamycin or other anthracyclines, with the total cumulative dose (doxorubicin equivalent) ≥350 mg/m^2.

    4. History of allergy (except local injection reaction) or intolerance to bortezomib;or one of the following conditions occurred with prior bortezomib regimens: no treatment response (not reach MR),disease progression within 6 months after the end of last dose.

    5. History of contraindications or intolerance to dexamethasone.

    6. Any anti-myeloma drug treatment or radiotherapy within 4 weeks prior to the first dose; or enrolled in any other clinical trials of anti-myeloma drug within 3 months prior to the first dose.

    7. History of autologous hematopoietic stem cell transplantation within 6 months prior to screening.

    8. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

    9. Adverse events from the previous treatment have not resolved to ≤ Grade 1 (except for alopecia, hyperpigmentation).

    10. Patients with persistent Grade≥2 peripheral neuropathy or Grade 1 peripheral neuropathy with pain.

    11. Patients with impaired cardiac function or significant cardiac disease.

    12. HBsAg/HBcAb positive with HBV-DNA titer higher than the lower limit of the test value of the research center, or HCV antibody positive with HCV-RNA titer higher than the lower limit of the test value of the research center,or human immunodeficiency virus (HIV) antibody positive.

    13. Patients with obvious digestive system dysfunction, which may affect intake, transport and absorption of the study drug.

    14. Active bacterial, fungal or viral infections that require systemic treatment within 1 week prior to the first dose

    15. Patients underwent major surgery within 6 weeks prior to the first dose, or had a surgical schedule during the study period;

    16. History of additional malignant tumor within 5 years, except for locally curable cancer that has been cured.

    17. Other medical conditions that, in the judgment of the investigator, may affect the patient's participation in this study.

    18. Pregnant or breastfeeding women;

    19. Not suitable for this study as decided by the investigator due to other reasons.

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1Beijing Chaoyang Hospital, Capital Medical UniversityBeijingBeijingChina

    Sponsors and Collaborators

    • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

    Investigators

    • Principal Investigator: Wenming Chen, Beijing Chaoyang Hospital affiliated to Capital Medical University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
    ClinicalTrials.gov Identifier:
    NCT05052970
    Other Study ID Numbers:
    • HE071-CSP-023
    First Posted:
    Sep 22, 2021
    Last Update Posted:
    Feb 1, 2022
    Last Verified:
    Jan 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 1, 2022